We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Iksuda

News List

Iksuda, LegoChem Expand ADC Alliance contractpharma
June 23, 2021
Grants Iksuda access to LegoChem's next generation ADC platform for up to six targets.
Iksuda Therapeutics raises $47m to progress ADC pipeline pharmatimes
June 08, 2021
Newcastle, UK-headquartered Iksuda Therapeutics has announced the closing of a $47m (£34m) financing round, with the funds to be used to support the advancement of its lead antibody drug conjugate (ADC) assets.
Iksuda Therapeutics and Femtogenix Sign License Agreement pharmafocusasia
March 07, 2019
Iksuda Therapeutics (Iksuda), the next-generation Antibody Drug Conjugate (ADC) company, today announced it has signed a licensing agreement with Femtogenix Limited (FGX), the next-generation ADC payload company.